Should I buy or sell TScan Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TScan Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TCRX shares. View TCRX analyst ratings or view top-rated stocks .

What is TScan Therapeutics' stock price target for 2024?

3 brokerages have issued 12 month price objectives for TScan Therapeutics' shares. Their TCRX share price targets range from $10.00 to $15.00. On average, they anticipate the company's share price to reach $12.50 in the next twelve months. This suggests a possible upside of 83.3% from the stock's current price. View analysts price targets for TCRX or view top-rated stocks among Wall Street analysts .

How have TCRX shares performed in 2024?

TScan Therapeutics' stock was trading at $5.83 at the beginning of 2024. Since then, TCRX shares have increased by 17.0% and is now trading at $6.82. View the best growth stocks for 2024 here .

When is TScan Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TCRX earnings forecast .

How were TScan Therapeutics' earnings last quarter?

TScan Therapeutics, Inc. (NASDAQ:TCRX) issued its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.08. The company had revenue of $7.21 million for the quarter, compared to analyst estimates of $2.94 million. TScan Therapeutics had a negative net margin of 423.86% and a negative trailing twelve-month return on equity of 60.65%.

What ETF holds TScan Therapeutics' stock?

Simplify Propel Opportunities ETF holds 1,046,916 shares of TCRX stock, representing 7.98% of its portfolio.

When did TScan Therapeutics IPO?

TScan Therapeutics (TCRX) raised $100 million in an initial public offering (IPO) on Friday, July 16th 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share.

Who are TScan Therapeutics' major shareholders?

TScan Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Cannon Global Investment Management LLC (0.04%). Insiders that own company stock include Barbara Klencke, Brian M Silver , David P Southwell, Gavin Macbeath , Lynx1 Capital Management Lp, Timothy J Barberich and Zoran Zdraveski . View institutional ownership trends .

How do I buy shares of TScan Therapeutics?

Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TCRX

TScan Therapeutics (TCRX) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free TCRX Stock Alerts

$6.82

-0.10 (-1.45%)

(As of 04/19/2024 ET)

Compare

Today's Range: $6.71
▼
$7.13
50-Day Range: $5.73
▼
$8.30
52-Week Range: $1.62
▼
$9.00

Volume: 278,857 shs
Average Volume: 284,545 shs
Market Capitalization: $326.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.50

Get TScan Therapeutics alerts:

TScan Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 83.3% Upside
$12.50 Price Target
Short Interest: Healthy
0.60% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.47
Based on 19 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.04) to ($1.09) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.84 out of 5 stars

Medical Sector

608th out of 911 stocks

Biological Products, Except Diagnostic Industry

99th out of 148 stocks

3.5

Analyst's Opinion

Consensus Rating
TScan Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
TScan Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.60% of the float of TScan Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
TScan Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in TScan Therapeutics has recently increased by 16.52%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
TScan Therapeutics does not currently pay a dividend.
Dividend Growth
TScan Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TCRX.

2.5

News and Social Media Coverage

News Sentiment
TScan Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 19 news articles for TScan Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 2 people have searched for TCRX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
3 people have added TScan Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TScan Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.27% of the stock of TScan Therapeutics is held by insiders.
Percentage Held by Institutions
82.83% of the stock of TScan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for TScan Therapeutics are expected to decrease in the coming year, from ($1.04) to ($1.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TScan Therapeutics is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TScan Therapeutics is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TScan Therapeutics has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About TScan Therapeutics Stock (NASDAQ:TCRX)

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

TCRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TCRX Stock News Headlines

April 20, 2024 | americanbankingnews.com

Research Analysts Set Expectations for TScan Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TCRX)

April 19, 2024 | globenewswire.com

TScan Therapeutics Announces Closing of Upsized Public Offering

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 19, 2024 | americanbankingnews.com

Brokers Set Expectations for TScan Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:TCRX)

April 19, 2024 | americanbankingnews.com

TScan Therapeutics (NASDAQ:TCRX) Rating Reiterated by Wedbush

April 18, 2024 | investing.com

TScan launches $125 million public stock offering

April 17, 2024 | finanznachrichten.de

TScan Therapeutics, Inc.: TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

April 17, 2024 | markets.businessinsider.com

TScan Therapeutics Announces Pricing Of Public Offering - Quick Facts

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 17, 2024 | finance.yahoo.com

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

April 16, 2024 | finance.yahoo.com

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

April 16, 2024 | globenewswire.com

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

April 8, 2024 | markets.businessinsider.com

TScan Therapeutics Appoints Chrystal Louis As Chief Medical Officer - Quick Facts

April 8, 2024 | markets.businessinsider.com

TScan Therapeutics Appoints Louis As CMO

April 8, 2024 | finance.yahoo.com

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

April 8, 2024 | globenewswire.com

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.

April 2, 2024 | globenewswire.com

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

March 26, 2024 | finance.yahoo.com

Hedge funds investors control 50% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 16%

March 17, 2024 | investorplace.com

Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With

March 11, 2024 | markets.businessinsider.com

Positive Outlook for TScan Therapeutics with Promising Clinical Trials and Strong Financial Position

March 7, 2024 | markets.businessinsider.com

Strong Buy Rating for TScan Therapeutics Amidst Promising Drug Developments and Financial Health

March 7, 2024 | markets.businessinsider.com

Buy Rating Affirmed for TScan Therapeutics Following Promising Phase 1 Results

March 7, 2024 | finance.yahoo.com

TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline

March 6, 2024 | benzinga.com

TScan Therapeutics: Q4 Earnings Insights

March 6, 2024 | investorplace.com

TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023

March 6, 2024 | globenewswire.com

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 28, 2024 | globenewswire.com

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

See More Headlines

Receive TCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/06/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:TCRX
CUSIP: N/A
CIK: 1783328
Web: www.tscan.com
Phone: 857-399-9500
Fax: N/A
Employees: 154
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.50
High Stock Price Target: $15.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +83.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-89,220,000.00
Net Margins: -423.86%
Pretax Margin: -423.86%
Return on Equity: -60.65%
Return on Assets: -33.86%

Debt

Debt-to-Equity Ratio: 0.18
Current Ratio: 6.51
Quick Ratio: 6.51

Sales & Book Value

Annual Sales: $21.05 million
Price / Sales: 15.51
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.15 per share
Price / Book: 2.17

Miscellaneous

Outstanding Shares: 47,880,000
Free Float: 43,922,000
Market Cap: $326.54 million
Optionable: Not Optionable
Beta: 0.90

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. Gavin MacBeath Ph.D. (Age 54)
CEO & Director
Comp: $650.17k
Dr. Stephen J. Elledge Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Mr. Tomasz Kula Ph.D.
Co-Founder & Member of Advisory Board
Mr. Jason A. Amello (Age 56)
Chief Financial Officer
Mr. Leiden Dworak M.B.A.
Principal Accounting Officer & Treasurer
Dr. Justin McCue Ph.D.
Chief Technology Officer
Ms. Ann Hargraves
Senior Vice President of Human Resources
Dr. Shrikanta Chattopadhyay M.D.
Senior VP & Head of Translational Medicine

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TCRX Stock Analysis - Frequently Asked Questions

Should I buy or sell TScan Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TScan Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TCRX shares.
View TCRX analyst ratings or view top-rated stocks.
What is TScan Therapeutics' stock price target for 2024?: 3 brokerages have issued 12 month price objectives for TScan Therapeutics' shares. Their TCRX share price targets range from $10.00 to $15.00. On average, they anticipate the company's share price to reach $12.50 in the next twelve months. This suggests a possible upside of 83.3% from the stock's current price.
View analysts price targets for TCRX or view top-rated stocks among Wall Street analysts.
How have TCRX shares performed in 2024?: TScan Therapeutics' stock was trading at $5.83 at the beginning of 2024. Since then, TCRX shares have increased by 17.0% and is now trading at $6.82.
View the best growth stocks for 2024 here.
When is TScan Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our TCRX earnings forecast.
How were TScan Therapeutics' earnings last quarter?: TScan Therapeutics, Inc. (NASDAQ:TCRX) issued its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.08. The company had revenue of $7.21 million for the quarter, compared to analyst estimates of $2.94 million. TScan Therapeutics had a negative net margin of 423.86% and a negative trailing twelve-month return on equity of 60.65%.

What ETF holds TScan Therapeutics' stock?: Simplify Propel Opportunities ETF holds 1,046,916 shares of TCRX stock, representing 7.98% of its portfolio.
When did TScan Therapeutics IPO?: TScan Therapeutics (TCRX) raised $100 million in an initial public offering (IPO) on Friday, July 16th 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share.
Who are TScan Therapeutics' major shareholders?: TScan Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Cannon Global Investment Management LLC (0.04%). Insiders that own company stock include Barbara Klencke, Brian M Silver, David P Southwell, Gavin Macbeath, Lynx1 Capital Management Lp, Timothy J Barberich and Zoran Zdraveski.
View institutional ownership trends.
How do I buy shares of TScan Therapeutics?: Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TCRX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial